Literature DB >> 14991150

Manipulation of glycogen-synthase kinase-3 activity in KSHV-associated cancers.

Masahiro Fujimuro1, S Diane Hayward.   

Abstract

The Kaposi's sarcoma-associated herpesvirus, KSHV, is associated with cancers that have increased incidence in patients who are also HIV positive or who have undergone organ transplantation. It has recently been observed that beta-catenin is overexpressed in two KSHV-associated cancers, Kaposi's sarcoma and primary effusion lymphoma. Investigation of the underlying defect in beta-catenin regulation revealed that the KSHV-encoded LANA protein stabilizes beta-catenin by binding to the negative regulator GSK-3, causing a cell-cycle-dependent nuclear accumulation of GSK-3. Thus, redistribution of GSK-3 has been identified as yet another mechanism through which beta-catenin can be dysregulated and contribute to human cancer. Copyright 2004 Springer-Verlag

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14991150     DOI: 10.1007/s00109-003-0519-7

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  123 in total

Review 1.  Molecular piracy of Kaposi's sarcoma associated herpesvirus.

Authors:  J Choi; R E Means; B Damania; J U Jung
Journal:  Cytokine Growth Factor Rev       Date:  2001 Jun-Sep       Impact factor: 7.638

2.  Axin-mediated CKI phosphorylation of beta-catenin at Ser 45: a molecular switch for the Wnt pathway.

Authors:  Sharon Amit; Ada Hatzubai; Yaara Birman; Jens S Andersen; Etti Ben-Shushan; Matthias Mann; Yinon Ben-Neriah; Irit Alkalay
Journal:  Genes Dev       Date:  2002-05-01       Impact factor: 11.361

3.  Nucleotide sequence of the Kaposi sarcoma-associated herpesvirus (HHV8).

Authors:  J J Russo; R A Bohenzky; M C Chien; J Chen; M Yan; D Maddalena; J P Parry; D Peruzzi; I S Edelman; Y Chang; P S Moore
Journal:  Proc Natl Acad Sci U S A       Date:  1996-12-10       Impact factor: 11.205

Review 4.  Molecular virology of Kaposi's sarcoma-associated herpesvirus.

Authors:  P S Moore; Y Chang
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2001-04-29       Impact factor: 6.237

5.  The latency-associated nuclear antigen tethers the Kaposi's sarcoma-associated herpesvirus genome to host chromosomes in body cavity-based lymphoma cells.

Authors:  M A Cotter; E S Robertson
Journal:  Virology       Date:  1999-11-25       Impact factor: 3.616

6.  Beta-catenin and cyclin D1 expression in human hepatocellular carcinoma.

Authors:  Tsuyoshi Ueta; Masahide Ikeguchi; Yasuaki Hirooka; Nobuaki Kaibara; Tadashi Terada
Journal:  Oncol Rep       Date:  2002 Nov-Dec       Impact factor: 3.906

7.  The oncogenic potential of Kaposi's sarcoma-associated herpesvirus cyclin is exposed by p53 loss in vitro and in vivo.

Authors:  Emmy W Verschuren; Juha Klefstrom; Gerard I Evan; Nic Jones
Journal:  Cancer Cell       Date:  2002-09       Impact factor: 31.743

Review 8.  Genetic alterations in hepatoblastoma and hepatocellular carcinoma: common and distinctive aspects.

Authors:  Marie Annick Buendia
Journal:  Med Pediatr Oncol       Date:  2002-11

9.  Role of Wnt pathway in medulloblastoma oncogenesis.

Authors:  Naoki Yokota; Shigeru Nishizawa; Seiji Ohta; Hiroaki Date; Haruhiko Sugimura; Hiroki Namba; Masato Maekawa
Journal:  Int J Cancer       Date:  2002-09-10       Impact factor: 7.396

10.  Nr-CAM is a target gene of the beta-catenin/LEF-1 pathway in melanoma and colon cancer and its expression enhances motility and confers tumorigenesis.

Authors:  Maralice E Conacci-Sorrell; Tamar Ben-Yedidia; Michael Shtutman; Elena Feinstein; Paz Einat; Avri Ben-Ze'ev
Journal:  Genes Dev       Date:  2002-08-15       Impact factor: 11.361

View more
  15 in total

Review 1.  The latency-associated nuclear antigen, a multifunctional protein central to Kaposi's sarcoma-associated herpesvirus latency.

Authors:  Mary E Ballestas; Kenneth M Kaye
Journal:  Future Microbiol       Date:  2011-12       Impact factor: 3.165

Review 2.  Glycogen synthase kinase-3 (GSK3): inflammation, diseases, and therapeutics.

Authors:  Richard S Jope; Christopher J Yuskaitis; Eléonore Beurel
Journal:  Neurochem Res       Date:  2006-08-30       Impact factor: 3.996

Review 3.  Gammaherpesvirus and lymphoproliferative disorders in immunocompromised patients.

Authors:  Ethel Cesarman
Journal:  Cancer Lett       Date:  2011-04-13       Impact factor: 8.679

4.  A purine scaffold HSP90 inhibitor BIIB021 has selective activity against KSHV-associated primary effusion lymphoma and blocks vFLIP K13-induced NF-κB.

Authors:  Ramakrishnan Gopalakrishnan; Hittu Matta; Preet M Chaudhary
Journal:  Clin Cancer Res       Date:  2013-07-23       Impact factor: 12.531

Review 5.  Molecular biology of Kaposi's sarcoma-associated herpesvirus and related oncogenesis.

Authors:  Qiliang Cai; Suhbash C Verma; Jie Lu; Erle S Robertson
Journal:  Adv Virus Res       Date:  2010       Impact factor: 9.937

6.  A Screen for Extracellular Signal-Regulated Kinase-Primed Glycogen Synthase Kinase 3 Substrates Identifies the p53 Inhibitor iASPP.

Authors:  Crystal Woodard; Gangling Liao; C Rory Goodwin; Jianfei Hu; Zhi Xie; Thaila F Dos Reis; Rob Newman; Heesool Rho; Jiang Qian; Heng Zhu; S Diane Hayward
Journal:  J Virol       Date:  2015-06-24       Impact factor: 5.103

7.  Protein complexes associated with the Kaposi's sarcoma-associated herpesvirus-encoded LANA.

Authors:  Rajeev Kaul; Subhash C Verma; Erle S Robertson
Journal:  Virology       Date:  2007-04-16       Impact factor: 3.616

Review 8.  Structure and function of latency-associated nuclear antigen.

Authors:  S C Verma; K Lan; E Robertson
Journal:  Curr Top Microbiol Immunol       Date:  2007       Impact factor: 4.291

9.  Accumulation of cytoplasmic beta-catenin and nuclear glycogen synthase kinase 3beta in Epstein-Barr virus-infected cells.

Authors:  David N Everly; Shuichi Kusano; Nancy Raab-Traub
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

Review 10.  Kaposi sarcoma-associated herpesvirus/human herpesvirus 8 and lymphoproliferative disorders.

Authors:  M-Q Du; C M Bacon; P G Isaacson
Journal:  J Clin Pathol       Date:  2007-12       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.